For the third quarter of the fiscal year ending March 2026, net sales were 464,554 million yen (0.8% increase YoY), operating income was 3,119 million yen (42.3% decrease YoY), and net income attributable to owners of the parent for the quarter was 5,889 million yen (8.8% decrease YoY).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"3151","jir_company_name":"Vital KSK Holdings, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/3151-20260210-01.pdf","jir_short_summary":"For the third quarter of the fiscal year ending March 2026, net sales were 464,554 million yen (0.8% increase YoY), operating income was 3,119 million yen (42.3% decrease YoY), and net income attributable to owners of the parent for the quarter was 5,889 million yen (8.8% decrease YoY).","jir_summary":"### Performance Overview\nFor the cumulative consolidated period of the third quarter of the fiscal year ending March 2026, net sales reached 464,554 million yen (0.8% increase YoY), operating income was 3,119 million yen (42.3% decrease YoY), and net income attributable to owners of the parent for the quarter was 5,889 million yen (8.8% decrease YoY). Core operating income before R&D expenses in the pharmaceutical business, a new business segment, was 4,002 million yen (74.0% compared to operating income YoY). Ordinary income was 6,692 million yen (4.2% increase YoY). By segment, the pharmaceutical wholesale business recorded net sales of 436,971 million yen (100.6% YoY) and operating income of 3,816 million yen (75.2% YoY). The pharmacy business reported net sales of 14,975 million yen (102.0% YoY) and operating income of 187 million yen (109.1% YoY). The animal pharmaceutical wholesale business had net sales of 9,488 million yen (108.2% YoY) and operating income of 221 million yen (91.1% YoY). The pharmaceutical business is a new segment with no recorded sales and a segment loss of 895 million yen. The nursing care rental and other businesses achieved net sales of 3,118 million yen (101.5% YoY) with an operating loss of 146 million yen.\n\n### Financial Position and Dividend Status\nAs of the third quarter of the fiscal year ending March 2026, total assets stood at 344,402 million yen, net assets at 111,437 million yen, and the equity ratio was 31.9%. The number of outstanding shares was 51,902,976 shares, with treasury stock amounting to 3,525,889 shares. The dividend was 34 yen per share at the end of the second quarter for fiscal 2026, with a year-end forecast of 34 yen, totaling an annual dividend forecast of 68 yen, representing an increase from the previous year's actual dividend of 45 yen. The company intends to continue promoting capital cost-conscious management under its medium-term management plan while focusing on growth investments and strengthening profitability.","jir_financial_highlights":"Net Sales: 464,554 million yen (0.8% increase YoY)\nCore Operating Income: 4,002 million yen (Unknown (74.0% compared to operating income YoY))\nOperating Income: 3,119 million yen (42.3% decrease YoY)\nOrdinary Income: 6,692 million yen (4.2% increase YoY)\nNet Income Attributable to Owners of Parent for the Quarter: 5,889 million yen (8.8% decrease YoY)\nTotal Assets: 344,402 million yen (Unknown)\nNet Assets: 111,437 million yen (Unknown)\nEquity Ratio: 31.9% (Unknown)\nAnnual Dividend Forecast: 68.00 yen (Unknown)\nNumber of Outstanding Shares (Common Stock): 51,902,976 shares (Unknown)","jir_category":"","jir_hashtags":"#VitalKSKHoldingsInc, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Net Sales: 464,554 million yen (0.8% increase YoY)\nOperating Income: 3,119 million yen (42.3% decrease YoY)\nNet Income Attributable to Owners of Parent for the Quarter: 5,889 million yen (8.8% decrease YoY)","jir_meta_title":"Vital KSK Holdings, Inc. Q3 Fiscal Year Ending March 2026 Financial Summary - Net Sales 464,554 million yen","jir_meta_description":"Vital KSK Holdings, Inc. Q3 financial summary for the fiscal year ending March 2026 reporting net sales of 464,554 million yen (0.8% increase YoY), operating income of 3,119 million yen (42.3% decrease YoY), and net income attributable to owners of the parent for the quarter of 5,889 million yen (8.8% decrease YoY).","jir_og_title":"Vital KSK Holdings, Inc. Q3 Fiscal Year Ending March 2026 Financial Summary","jir_og_description":"Net sales for the third quarter of the fiscal year ending March 2026 were 464,554 million yen, operating income was 3,119 million yen, and net income attributable to owners of the parent for the quarter was 5,889 million yen.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Sales Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 March Q3\\\",\\\"FY2026 March Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[460680,464554],\\\"backgroundColor\\\":\\\"#4e73df\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 March Q3\\\",\\\"FY2026 March Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[5406,3119],\\\"backgroundColor\\\":\\\"#1cc88a\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent for the Quarter Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 March Q3\\\",\\\"FY2026 March Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Quarterly Net Income\\\",\\\"data\\\":[6459,5889],\\\"backgroundColor\\\":\\\"#f6c23e\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Net Sales Breakdown (Million Yen) FY March 2026 Q3\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceutical Wholesale Business\\\",\\\"Pharmacy Business\\\",\\\"Animal Pharmaceutical Wholesale Business\\\",\\\"Nursing Care Rental & Other Businesses\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[436971,14975,9488,3118],\\\"backgroundColor\\\":[\\\"#4e73df\\\",\\\"#1cc88a\\\",\\\"#36b9cc\\\",\\\"#f6c23e\\\"]}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_operating_profit_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Operating Income Breakdown (Million Yen) FY March 2026 Q3\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceutical Wholesale Business\\\",\\\"Pharmacy Business\\\",\\\"Animal Pharmaceutical Wholesale Business\\\",\\\"Nursing Care Rental & Other Businesses\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[3816,187,221,-146],\\\"backgroundColor\\\":[\\\"#4e73df\\\",\\\"#1cc88a\\\",\\\"#36b9cc\\\",\\\"#e74a3b\\\"]}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":16948,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-26470","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n